To demonstrate if once-daily dosing of ADVAIR 100/50 once-daily has superior efficacy and
comparable safety compared with FP 100mcg once-daily in pediatric subjects 4 to 11 years of
age with asthma.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Salmeterol Xinafoate